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Abstract Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food
and Drug Administration for prophylaxis of venous thromboembolism in adult patients
hospitalized for an acute illness at risk for thromboembolic complications. Assessment
of the anti-coagulant effect of betrixaban may be useful in some situations. Also,
clinicians need to know how routine coagulation assays are influenced.
Objective The aim of this study is to determine which coagulation assay(s) should be
used to assess the impact of betrixaban on haemostasis and provide laboratory
guidance for their interpretation.
Materials and Methods Betrixaban was spiked at final concentrations ranging from 0
to 250 ng/mL in platelet-poor plasma. Different reagents from several manufacturers
were tested and the impact of betrixaban on pro-thrombin time (PT), activated partial
thromboplastin time (aPTT), dilute Russel viper venom time (dRVV-T), chromogenic
anti-Xa assays, thrombin generation assay (TGA), and a large panel of haemostasis
diagnostic tests has been assessed.
Results A concentration-dependent prolongation of aPTT, PT and dRVV-T is observed.
The sensitivity mainly depends on the reagent. Chromogenic anti-Xa assays show high
sensitivity depending on the reagent and/or the methodology. These assays applicable
for other direct factor Xa inhibitors have to be adapted to obtain a relevant range of
measurement. TGA may also be attractive to assess the anti-coagulant activity of
betrixaban.
Conclusion Adapted chromogenic anti-Xa assays are the most appropriate assays to
estimate the concentration of betrixaban. Betrixaban significantly affects several
haemostasis diagnostic tests and this needs to be taken into consideration when
requesting and interpreting such tests.
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Coagulation and Fibrinolysis
Introduction
Betrixaban, a novel direct oral factor Xa (FXa) inhibitor
developed by Portola Pharmaceuticals Inc., has received its
market authorization under the brand name of BevyxXa on
the 23rd of June 2017 in the United States for the prophylaxis
of venous thromboembolisms (VTE) in adult patients.1 The
approval was based on the data from the Acute Medically Ill
Prevention with Extended Duration Betrixaban Study, a
randomized, double-blind, multi-national clinical trial com-
paring extended duration betrixaban to short duration enox-
aparin in the prevention of VTE in an acutely medically ill
hospitalized population with risk factors for VTE.2–6 It has
been developed to have a low renal clearance (< 7% of
administered dose), a minimal hepatic metabolism (< 1%)
and a long half-life (37 hours).7 Although direct oral anti-
coagulants (DOACs) do not require routine monitoring, the
assessment of their effect on coagulation may be useful in
some clinical situations (e.g., detection of drug accumulation
in acute renal or hepatic failure; planning the timing of
urgent invasive procedure; recurrence of stroke or bleedings,
etc.).3,8 In this study, spiked plasma has been used to realize
calibration curve. This technique has already been used in
the past for the assessment of other DOACs.9–12 It has been
found that we can reliably apply these results in real-life
samples. Indeed, some studies revealed similarities between
in vitro and ex vivo data for rivaroxaban.13–15
The primary aim of this study is to assess and compare the
performance of routinely used andmore specific coagulation
assays tomeasure the anti-coagulant effect of betrixaban and
estimate its plasma concentration. In addition, good labora-
tory recommendations for the interpretation of haemostasis
diagnostic tests that may be affected by betrixaban will be
provided.
Materials and Methods
Betrixabanwas spiked at increasing concentrations in pooled
citrated normal human platelet-poor plasma (PPP). The
tested concentrations cover the on-therapy range
(from  9 ng/mL at Ctrough to  122 ng/mL at Cmax for the
40 and 120 mg once daily doses, respectively, according to
the clinical pharmacology and biopharmaceutics reviews of
the Center for Drug Evaluation and Research).16
Testing Solutions of Betrixaban
Betrixaban (molecular weight: 451.90 g/mol; purity
¼ 92.35%) was obtained from ChemScene (Monmouth
Junction, New Jersey, United States). A stock solution at
1.0 mg/mL in dimethyl sulfoxide (DMSO) was obtained and
intermediate solutions at 100, 300, 500, 1,000, 1,500 and
2,500 ng/mL diluted in phosphate-buffered saline without
Ca2þ and Mg2þ were prepared. Working solutions of 10, 30,
50, 100, 150 and 250 ng/mL of betrixaban were obtained by
mixing these stock solutions with normal pooled plasma
(NPP) (1:9 v/v). According to purity, these concentrations
represented 9.2, 27.7, 46.2, 92.4, 138.5 and 230.9 ng/mL
of active betrixaban, respectively, in plasma. The DMSO
concentration in plasma was  0.05% (v/v) which did not
influence the coagulation.17
Preparation of Platelet-Poor Plasma
Fifty-six individuals were included in the study. The exclu-
sion criteria were thrombotic and/or haemorrhagic events,
anti-platelet and/or anti-coagulant medication, hormonal
therapy, pregnancy and uptake of drugs potentially affecting
the platelet and/or coagulation factor functions during the
2 weeks prior to the blood drawn. The study protocol is in
accordancewith the Declaration of Helsinki. Bloodwas taken
by venipuncture in the antecubital vein and collected into
0.109 M sodium citrate (9:1 v/v) tubes (Venosafe, Terumo,
Belgium) using a 21-gauge needle (Terumo). The PPP was
obtained from the supernatant fraction of blood tubes after a
double centrifugation for 15 minutes at 1,500  g at room
temperature. Immediately after centrifugation, PPP from the
56 donors were brought together to obtain the NPP which
was frozen at –80°C without any delay. Frozen NPP samples
were thawed and heated to 37°C for 5 minutes just before
experiment. All tests were performed within 4 hours after
thawing.
Routinely Used and Specific Coagulation Assays
A summary of the different assays and their reagents per-
formed in this study is provided in►Table 1. Several reagents
have been used for some tests. All tests were performed in
accordance with the recommendations of the manufacturers,
or otherwise this is specified in the sections below. Depending
on the test and reagent, evaluationswere performed on a STA-
R Evolution (Diagnostica Stago, Asnières-sur-Seine, France), a
STA-R Max (Diagnostica Stago), an ACL-TOP 700 (Instrumen-
tation Laboratory, Lexington, Kentucky, United States) or an
Ascent Fluoroscan (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, United States) using the calibrated automated
thrombogramsoftware (CAT, ThrombinoscopeBV,Maastricht,
The Netherlands) (►Table 1).
Pharmacodynamics Assays
To evaluate the anti-coagulant effect of betrixaban, pro-
thrombin time (PT), activated partial thromboplastin time
(aPTT), dilute Russell viper venom time (dRVV-T), chromo-
genic anti-Xa assays and the thrombin generation assay
(TGA) were assessed. PT, aPTT, dRVV-T and TGA were per-
formed in accordance with the recommendations of the
manufacturer.
For all chromogenic anti-Xa assays, the results were
collected as optical densitometry (OD)/min by using several
reagents and methodologies (►Table 1).
For STA-Liquid Anti-Xa, DiXaI and Technochrom Anti-Xa
assays, the methodologies provided by the manufacturer for
the assessment of rivaroxaban were used but the tests were
not calibrated with rivaroxaban calibrators and results were
reported as OD/min.
For the following anti-Xa chromogenic assays, an adapted
method was proposed with the aim of increasing the
dynamic range of quantitation. For Biophen Heparin LRT,
50 µL of spiked NPP diluted at 1:10 or 1:2 in physiological
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Table 1 Overview of the different assays performed in this study
Coagulation assay Reagent Manufacturer Method Coagulation analyser
(manufacturer)
Pro-thrombin time TriniCLOT PT Excel S Tcoag, Bray, Ireland Chronometric STA-R Evolution
(Diagnostica Stago)TriniCLOT PT Excel
TriniCLOT PT HTF
STA-NeoplastineR Diagnostica Stago,
Asnieres, FranceSTA-Neoplastine CIþ
Dade Innovin Siemens Healthcare
Diagnostics, Deerfield,
Illinois, United States
RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Activated partial
thromboplastin time
STA-C.K.Prest Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)STA-Cephascreen
STA-PTT Automate
Actin FS Siemens Healthcare
Diagnostics, Deerfield,
Illinois, United States
SynthASil Instrumentation
Laboratory, Lexington,
Kentucky, United
States
SynthAfax ACL-TOP
(Instrumentation
Laboratory)
Thrombin time STA-Thrombin Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
Lupus anti-coagulant STA-Staclot DRVV
Screen
Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
STA-Staclot DRVV
Confirm
Reptilase time STA-Reptilase Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
Anti-thrombin STA-Stachrom ATIII Diagnostica Stago,
Asnieres, France
Chromogenic
(thrombin-based)
STA-R Evolution
(Diagnostica Stago)
HemosIL Liquid
Antithrombin
Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chromogenic
(FXa-based)
ACL-TOP
(Instrumentation
Laboratory)
Chromogenic anti-Xa
assays
Biophen Direct Factor
Xa Inhibitors
Hyphen BioMed,
Neuville-sur-Oise,
France
Chromogenic STA-R Evolution
(Diagnostica Stago)
Biophen Heparin LRT
STA-Liquid Anti-Xa Diagnostica Stago,
Asnieres, France
Technochrom Anti-Xa Technoclone, Vienna,
Austria
HemosIL Liquid
Heparin
Instrumentation
Laboratory, Lexington,
Kentucky, United
States
ACL-TOP
(Instrumentation
Laboratory)
Thrombin generation
assay
PPP-Reagent Low Thrombinoscope BV,
Maastricht, The
Nederland’s
Fluorimetric Calibrated Automated
Thrombogram
(Thrombinoscope BV)
PPP-Reagent
PPP-Reagent High
(Continued)
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saline were mixed with 125 µL of chromogenic substrate
(SXa-11) and incubated for 240 seconds at 37°C. Then,
125 µL of bovine FXa pre-warmed at 37°C was added. For
HemosIL Liquid Heparin, 200µL of spiked NPP was mixed
with 100 µL of chromogenic substrate (S2732) and incubated
for 180 seconds at 37°C. Thereafter, 75 µL of bovine FXa was
added. For DiXaI, two procedures were used (normal or low).
Briefly, 200 µL of spiked NPP diluted at 1:50 (normal proce-
dure) or 1:15 (low procedure) in Tris-NaCl-ethylenediami-
netetraacetic acid (EDTA) reaction buffer provided by the
manufacturer was mixed with 75 µL of human FXa and
incubated for 120 seconds at 37°C. Then, 75 µL of FXa-
specific chromogenic substrate (CS11(65)) pre-warmed at
37°C was added. For STA-Liquid anti-Xa, 30 µL of spiked NPP
diluted at 1:4 in physiological saline was mixed with 150 µL
of chromogenic substrate (CBS 02.44) and incubated for
240 seconds at 37°C. Then, 150 µL of bovine FXa pre-warmed
at 37°C was added. Finally, for Technochrom Anti-Xa, 85µL of
spiked NPP diluted 1:15 or 1:5 in Tris-EDTA buffer provided
by themanufacturer wasmixedwith 85 µL of bovine FXa and
incubated for 240 seconds at 37°C. Then, 85 µL of chromo-
genic substrate pre-warmed at 37°Cwas added. All measure-
ments were performed on STA-R Evolution.
Diagnostic Assays
The influence of betrixaban on the following diagnostic tests
has also been investigated. Thus, in addition to PT, aPTT and
dRVV-T, which could be useful for the assessment of betrix-
aban as described above, Fibrinogen (Fib), clotting factors,
protein C and S and anti-thrombin (AT) measurements,
thrombin time (TT) and reptilase time (RT) have also been
performed. Investigations for lupus anti-coagulant (LA) and
activated protein C resistance were also assessed.
Determination of Lupus Anti-Coagulant: Dilute Russell Viper
Venom Time
The diagnosis of anti-phospholipid syndrome can be done by
the estimation of the percentage of correction obtained with
the dRVV-T: (Screen – Confirm)/Screen)100. The cut-off of
5% of correction is proposed by the British Committee for
Standards in Haematology guidelines for the investigation of
LA (reference ratio is 0.9:1.05).18
Anti-Thrombin Measurement
Antithrombin measurement was performed using the STA-
Stachrom ATIII (Diagnostica Stago), a chromogenic assay
based on the inhibition of bovine FIIa, and the HemosIL
Liquid Antithrombin (Instrumentation Laboratory), a chro-
mogenic assay based on the inhibition of bovine FXa.
Fibrinogen Measurement (Clauss Method and PT-Derived)
For the Clauss method, 150 µL of plasma diluted at 1:20 with
saline solutionwas incubated for 240 seconds. Then, 50 µL of
STA-Liquid Fib (Diagnostica Stago) was added to trigger the
coagulation. For the PT-derivedmethod, 50 µL of plasmawas
mixed with 100 µL of RecombiPlasTin 2G (Instrumentation
Laboratory) to trigger the coagulation.
Thrombin Time
Thrombin time was investigated with the STA-Thrombin
(Diagnostica Stago) according to the recommendations of
the manufacturer.
Table 1 (Continued)
Coagulation assay Reagent Manufacturer Method Coagulation analyser
(manufacturer)
Evaluation of extrinsic
clotting factor levels
RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric STA-R Max
(Diagnostica Stago)
Evaluation of intrinsic
clotting factor levels
STA-C.K.Prest Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Fibrinogen Clauss
method
STA-Liquid Fib Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Fibrinogen PT-derived RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric ACL-TOP
(Instrumentation
Laboratory)
Protein S Protein S Activity Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric ACL-TOP
(Instrumentation
Laboratory)
Protein C STA-Stachrom Protein
C
Diagnostica Stago,
Asnieres, France
Chromogenic STA-R Max
(Diagnostica Stago)
Activated protein C
resistance
STA-Staclot APC-R Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Abbreviations: PPP, platelet-poor plasma; PT, pro-thrombin time.
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Reptilase Time
Reptilase time was investigated using STA-Reptilase (Diag-
nostica Stago) according to the recommendations of the
manufacturer.
Protein C Activity Measurement
The activity of protein C was investigated using STA-Sta-
chrom Protein C (Diagnostica Stago) according to the recom-
mendations of the manufacturer.
Protein S Activity Measurement
The activity of protein S was investigated using Protein S
Activity (Instrumentation Laboratory) according to the
recommendations of the manufacturer.
Assessment of Activated Protein C Resistance
The activity of protein C resistance was investigated using
STA-Staclot APC-R (Diagnostica Stago) according to the
recommendations of the manufacturer.
Measurement of Clotting Factors
Intrinsic clotting factors activity (VIII, IX, XI and XII) was
assessed using STA-C.K.Prest (Diagnostica Stago). Fifty
microlitre of spiked NPP diluted at 1:10, 1:20 or 1:40 in
physiological saline was incubated for 240 seconds at 37°C
after adding 50 µL of deficient plasma (Diagnostica Stago)
and 50 µL of STA-C.K.Prest. Coagulation was then triggered
by adding 50 µL of CaCl2 0.025 M. Extrinsic clotting factors
activity (II, V, VII and X) was assessed using RecombiPlasTin
2G. Fiftymicrolitre of spikedNPP diluted at 1:10, 1:20 or 1:40
in physiological salinewas incubated for 240 seconds at 37°C
after adding 50 µL of deficient plasma. Coagulationwas then
triggered by adding 100 µL of RecombiPlasTin 2G. All mea-
surements were performed on a STA-R Max coagulometer.
Statistical Analysis
Statistical analyses and graphics were computed using
GraphPad Prism 5.04 for Windows 7 Professional (GraphPad
Software, La Jolla, California, United States).
To compare the sensitivity of the different clotting assays,
the concentration of betrixaban needed to double the clot-
ting time (2  CT [CT ¼ clotting time]) was used. For chro-
mogenic assays, the sensitivity is defined as the
concentration of betrixaban needed to halve the analytical
parameter (1/2  OD/min [the concentration needed to
halve the change in the OD reported by minute]). For the
CAT, the sensitivity of the different parameters is defined as
follow: Cmax IC50 (the concentration reducing the Cmax of
50%); peak IC50 (the concentration reducing the peakof 50%);
mVRI IC50 (the concentration reducing the mVRI of 50% [the
mean velocity rate index (mVRI) represents the effective rate
of thrombin generation (i.e., the slope) between lag time and
time to peak]); mVRI ¼ Peak/(time to peak – lag time);
2  LT (the concentration needed to double the lag time
[LT]); 2  TTP (the concentration needed to double the time
to peak [TTP]).
Except for clotting factor activities that were run only
once, each test was run in triplicate on the same day. Data on
the graphics represent the mean of triplicates. The repeat-
ability is defined as the mean of the coefficient of variation
(CV) ([standard deviation/mean]100) of the triplicate of
each concentration for each test.
For tests evaluated for the assessment of the pharmaco-
dynamics of betrixaban (i.e., aPTT, PT, chromogenic anti-Xa
assays, dRVV-T and CAT), the limit of detection (LOD) and
quantitation (LOQ) were calculated as follow:
– LOD: [(3standard deviation of Y0)/slope]
– LOQ: [(10standard deviation of Y0)/slope]
where Y0 is the baseline value of the linear regression. For
assays that did not fit a linear response on their entire range of
measurement (i.e., BiophenDirect FactorXa inhibitors [DiXaI];
BiophenHeparin LRT; STA Liquid Anti-Xa; TechnochromAnti-
Xa normal and high; and HemosIL Liquid heparin), the first
points of the calibration curve were used to define a linear
regression. The slopeof this linear regressionwas thenused for
the calculation of the LOD and LOQ.
Results
Pharmacodynamics Assays
Pro-Thrombin Time
A concentration-dependent prolongation of PT was found.
The 2  CT depended on the reagent and ranged from
198 ng/mL (STA-NeoplastineR) to 514 ng/mL (Dade Innovin).
PT may be normal (ratio < 1.2) with on-therapy concentra-
tion of betrixaban depending on the reagent (►Fig. 1;
►Supplementary Fig. S1, online only). The repeatability
was always below 2%. The LOD and LOQ ranged from 5 to
36 ng/mL and from 11 to 107 ng/mL, respectively.
Activated Partial Thromboplastin Time
The aPTT showed a concentration-dependent prolongation
of clotting time. The 2  CT depended on the reagent and
ranged from 257 ng/mL (SynthAfax) to 479 ng/mL (STA C.K.
Prest) (►Fig. 2; ►Supplementary Fig. S2, online only). The
repeatability was always below 2%. The LOD and LOQ ranged
from 16 to 57 ng/mL and from 21 to 152 ng/mL, respectively.
Dilute Russell Viper Venom Time
STA-Staclot-DRVV Screen and Confirm were also prolonged
dose-dependently (►Fig. 3; ►Supplementary Fig. S3, online
only). The 2  CTwas 80 ng/mL for STA-Staclot-DRVV Screen
and 108 ng/mL for STA-Staclot-DRVV Confirm. The repeat-
ability ranged from 0.8% (STA-Staclot-DRVVConfirm) to 0.9%
(STA-Staclot-DRVV Screen). The LOD and LOQ were 5 and
17 ng/mL for the DRVV Screen and 6 and 22 ng/mL for DRVV
Confirm, respectively.
Chromogenic Anti-Xa Assays
A concentration-dependent decrease in OD/min was
observed (►Fig. 4; ►Supplementary Fig. S4, online only).
The reactions were fitted by an exponential model. The 1/2
OD/min ranged from 120 ng/mL (Biophen Heparin LRT Low)
to 569 ng/mL (TechnochromAnti-Xa High). The repeatability
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was from 0.6% (Biophen Heparin LRT) to 3.1% (HemosIL
Liquid Heparin). The LOD and LOQ ranged from 1 to
72 ng/mL and from 4 to 185 ng/mL, respectively.
Thrombin Generation Assay
The most influenced parameters were the peak (Cmax IC50: 8–
28ng/mL)andthemVRI (mVRI IC50: 7–10ng/mL),while thelag
time, the time to peak and the endogenous thrombinpotential
were less affected, as reported in ►Fig. 5. The prolongation/
inhibition of all parameters decreased inversely to the amount
of tissue factor (TF) in the reagent. The CVof the triplicate was
always below 10%. The LOD and LOQ for the peak ranged from
37 to 58 ng/mL and from 122 to 193 ng/mL, respectively. For
Fig. 1 Impact of betrixaban on pro-thrombin time (PT). Betrixaban
showed a concentration-dependent prolongation of the PT. The
relation was linear and the 2 x CT depended on the reagent. The
2  CTranged from 198 ng/mL for STA-NeoplastineR to 514 ng/mL for
Dade Innovin (r2: correlation coefficient; 2  CT: 2  clotting time
expressed in ng/mL; CV: coefficient of variation expressed in per-
centage [%]).
Fig. 3 Impact of betrixaban on the dilute Russell viper venom time
(dRVVT). Betrixaban prolonged the dilute Russell viper venom time
dose-dependently. The relation is curvilinear showing a lower sensi-
tivity at the higher concentrations (from 150 ng/mL). However, the
higher sensitivity at the lower concentrations is interesting since it
provides a low limit of detection and quantitation.
Fig. 2 Impact of betrixaban on activated partial thromboplastin time.
Betrixaban showed a concentration dependent prolongation of the
activated Partial Thromboplastin Time. The relation was curvilinear
and the 2CT depended on the reagent. The 2CT was ranging
from 257ng/mL for SynthAfax® to 479ng/mL for STA®-C.K. Prest®. (r2:
Correlation Coefficient; 2CT: 2 Clotting Time expressed in ng/mL;
CV: Coefficient of variation expressed in percentage [%]; NC; Not
calculated. The plateau does not reach a ratio of 2 for the concen-
trations tested in this study).
Fig. 4 Measurement of betrixaban with chromogenic anti-Xa assays.
There was a concentration-dependent decrease of the OD/min. Tests
with higher baseline OD/min had a wider range of quantitation
compared with those starting at lower OD/min at baseline (r2:
correlation coefficient; 1/2  OD/min: halve in optical density
by minute expressed in ng/mL; CV: coefficient of variation expressed
in percentage [%]). Some tests are not sufficiently influenced with the
current methodologies and need to be adapted.
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the mVRI, the LOD and LOQ ranged from 18 to 27 ng/mL and
from 66 to 88 ng/mL, respectively.
Diagnostic Assays
Determination of Lupus Anti-Coagulant: Dilute Russell
Viper Venom Time
A curvilinear prolongation of % correction was observed
(►Supplementary Fig. S5, online only). The cut-off of 5% of
correction was reached at betrixaban concentration of
38 ng/mL.
Fibrinogen, Anti-Thrombin, Protein C, ThrombinTime and
Reptilase Time Measurements
These assays were not influenced by the presence of betrix-
aban at the concentration tested in this study.
Protein S Measurement
Protein S measurement showed a concentration-dependent
linear prolongation (►Supplementary Fig. S6, online only).
The 2  CT was 253 ng/mL and the repeatability was 1.2%.
The LOD and LOQ were 12 to 22 ng/mL, respectively.
Assessment of Activated Protein C Resistance
Protein C resistance assessment showed a concentration-
dependent curvilinear prolongation (►Supplementary
Fig. S7, online only). The repeatability was 1.1%. The LOD
and LOQ were 7 and 15 ng/mL, respectively.
Clotting Factor Measurement
For factors of the intrinsic pathway (FVIII, FIX, FXI and FXII), the
aPTT-basedclottingmethodshowedameandecreaseof  7%at
10 ng/mL of betrixaban, 19% at 50 ng/mL and 42% at 150 ng/mL
with a diluted sample (1:10). The impactwasmore pronounced
for FXI and FVIII as presented in ►Supplementary Table S1
(onlineonly) and►Supplementary Fig. S8 (onlineonly). For FV,
FVII and FX, a mean decrease of 2% at 10 ng/mL of betrixaban,
10% at 50 ng/mL and 24% at 150 ng/mL was observed with a
dilution of 1:10, while pro-thrombin measurement seemed to
be less affected (maximal decrease of 6% at 150 ng/mL with a
dilution of 1:40) (►Supplementary Table S1, online only, and
►Supplementary Fig. S8, online only). A correction of the
impact of betrixaban was observed with higher dilution (i.e.,
1:20 or 1:40).
Discussion
The aim of this study was to investigate the impact of
betrixaban on a series of routine ormore specific coagulation
tests to provide good recommendations to estimate the anti-
coagulant effect of the treatment as well as to correctly
interpret the results of diagnostic tests, whichmay be altered
by the presence of this novel direct FXa inhibitor. Several
reagents andmethodologies have been assessed onNPP from
healthy volunteers spiked with betrixaban to provide good
laboratory practice at the laboratory level.
Some limitations of our study have to be recognized. One
limitation of this study is the use of NPP spiked with
Fig. 5 Impact of betrixaban on calibrated automated thrombogram
(CAT). The most influenced CAT parameters are the peak and the
mean velocity rate index. There is an inter-reagent variability. Thanks
to their low IC50 for the peak and the mVRI, the better resolution and
their large range of application, platelet-poor plasma (PPP)-Reagent
Low, PPP-Reagent and PPP-Reagent High seemed to be the best
reagents to monitor patients on betrixaban (ETP: endogenous
thrombin potential; IC50: half-maximum inhibitory concentration; LT:
lag time; mVRI: mean velocity rate index; TTP: time to peak). mVRI
was defined as: (Peak)/(Time to peak – Lag time).
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betrixaban. This technique has already been used in the past
for the assessment of other DOACs.9–12 It has been found that
we can reliably apply these results in real-life samples.
Indeed, some studies revealed similarities between in vitro
and ex vivo data for rivaroxaban13–15 and this might be
applicable to betrixaban. Further investigations are required
to confirm these data and evaluate the inter-individual
variability in patients treated with betrixaban.
Routinely Used and Specific Coagulation Assays:
Advantages and Drawbacks
Routine Tests and Derivation of Specific Assays Acting on
Factor X
Prothrombin time is broadly used to assess the impact of
DOAC therapy but failed to be recommended as the reference
assay for the assessment of direct FXa inhibitors.19According
to our results, PT is not sensitive enough to estimate betrix-
aban plasma concentrations and, depending on the reagent,
may be normal in presence of concentrations observed in the
on-therapy range. Thus, in addition to the biological and pre-
analytical variables that may affect PT, this inter-reagent
variability prevents valid recommendations of cut-offs
in seconds associated with a bleeding risk applicable to all
reagents. In addition, drugs or haematologic abnormalities
affecting at least one factor assessed by PT could also inter-
fere and bias the conclusions.10,20 Definitively, PT should not
be recommended to estimate plasma concentration of
betrixaban. This result corroborates previous investigations
about PT and DOACs (rivaroxaban, apixaban, dabigatran and
edoxaban).9,10,19,21
For aPTT, a concentration-dependent prolongation is
shown in presence of increasing doses of betrixaban. This
routine test is not sensitive enough to estimate betrixaban
plasma concentrations and depending on the reagent used, it
may not be influenced at concentrations observed in the on-
therapy range. aPTT should not be recommended to estimate
plasma concentration of betrixaban. The dependence of the
reagent has previously been investigated and observed for
dabigatran, apixaban, rivaroxaban and edoxaban.8,22,23
The dRVV-T is usually used for the assessment of anti-
phospholipid syndrome.24Previous studies suggested that this
test could be used for the evaluation of all DOACs but it has
never been assessed on betrixaban. The concentration-depen-
dent prolongation of dRVV-T showed a curvilinear correlation,
suggesting a plateauing effect at higher concentrations.25 The
reagents used present a high sensitivity to ensure a reliable
assessment of drug effect. These results are consistent with
results obtained with others direct FXa inhibitors.19,26,27
In previous studies, routine tests have already been
assessed to estimate the impact of DOACs in real-life sam-
ples9 and it has been demonstrated that PT and aPTTmay not
be adequate to estimate drug levels.19,28 For a particular
chronometric assay, the between-reagent variability could
be explained by the differences in the composition of the
reagent. The source of phospholipids (e.g., phosphatidylser-
ine, phosphatidylethanolamine or phosphatidylcholine),
their proportion in the reagent, as well as other factors
such as the ionic force, the pH, the source of TF (for PT) or
the activator (for aPTT) could provide some explanations.
Furthermore, Smith et al demonstrated that traces of acti-
vated FVII could modulate thromboplastin sensitivity to FV,
FVII, FX and pro-thrombin.29,30
Chromogenic anti-Xa assays have already been described
as accurate assays for the measurement of plasmatic drug
level of direct FXa inhibitors.8,10,22,31,32 The different chro-
mogenic assays available in the market used in this study
showed linear or exponential relations depending on the
reagent and the methodology applied. Compared with other
chromogenic anti-Xa assays, Biophen DiXaI is specific for
direct FXa inhibitors such as betrixaban.8,33 Namely, thanks
to its Tris/EDTA/NaCl buffer at pH ¼ 7.85, this assay is
insensitive to the presence of AT-dependent FXa inhibitors.34
However, it has been reported that the low procedure of the
Biophen DiXaI may not warrant the specificity for direct FXa
inhibitors anymore. This may be due to an insufficient
dilution of the plasma sample in the specific buffer35 (see
also the “Materials and Methods” section). As the low
procedure seems to be more recommended for the assess-
ment of betrixaban, thismay be a problem in case of bridging
therapy. Importantly and according to the dynamic range of
quantitation of the current chromogenic assays, further
investigations should be done to assess the on-therapy
concentration of betrixaban (►Table 2). The different sensi-
tivity observed with the different chromogenic anti-Xa
assays could be explained by differences in chromogenic
substrate, origin of FXa, as well as by the ratio between the
substrate and the FXa brought into the test.36 The ionic force
and the pH of the buffer solution could also be parameters
that can impact the sensitivity of a particular assay.9 Thus,
betrixaban does not respond similarly to chromogenic anti-
Xa assays than do other direct FXa inhibitors. This is due to
the low plasma concentrations observed in the clinical
development, which require tests sensitive at very low
equivalent plasma levels. Also, a different affinity for FXa
compared with other direct FXa inhibitors is possible, as
already observed between apixaban and rivaroxaban.37
Development of specific methodologies for betrixaban are
thus required, which may be a barrier to the development of
a universal chromogenic anti-Xa assay applicable to DOACs
and heparins.
The CAT gives more information than traditional coagula-
tion assays.38 By its mode of action, betrixaban mainly acts
on the amplification phase of the thrombin generation,
affecting mostly the peak and the mVRI. The sensitivity
towards the lag time and the time to peak depends on the
quantity of TF in the reagent. So, the sensitivity towards the
lag time decreaseswith the amount of TF in the reagent since
all reagent tested in this study contain 4 µM of phospholi-
pids. Inversely, the sensitivity towards the time to peak
increases with the amount of TF in the reagent.
Impact of betrixaban on Haemostasis Diagnosis
Assays
As other anti-coagulant drugs, betrixaban may affect the
results of a series of coagulation assays routinely used in case
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of thrombophilia or in the exploration of a haemorrhagic
event. Our results on routine tests (i.e., PT and aPTT) suggest
that sensitivity depends on the reagents used for a particular
assay and, thus, there is a need for clinicians to discuss with
the laboratory to knowwhether these tests are influenced by
betrixaban to avoid misdiagnosis and useless investigations
(►Table 3).
The ATmeasurement using FXa-based or FIIa-based chro-
mogenic assays are not influenced by betrixaban. Thus, in
patients treated with betrixaban, thrombin-based or FXa-
based chromogenic assays might be used for the assessment
of AT rate. Clinically relevant concentration of betrixaban
may interfere with the measurement of clotting factors.
However, the relation is not linear, as suggested by the
plateauing effect observed with the aPTT or the dRVV-T.
Dilution of the sample tends to reduce the drop of clotting
factors between baseline and high betrixaban concentration,
as already stated for rivaroxaban, apixaban and edoxa-
ban.9,10,39 As mentioned, the dRVV-T is affected by betrix-
aban, and prolongation of the clotting time may depend on
the concentration, the composition and the concentration of
phospholipids (i.e., as demonstrated in this study, the screen-
ing reagent is more sensitive than the confirm).25,29,30
Therefore, dRVV-T should be avoided for the assessment of
LA in patients treated with betrixaban since the ratio
between the screen and the confirmwill be increased giving
possible false-positive results. This has already been
reported with other direct FXa inhibitors.40 To avoid such
results, manufacturers aim to develop methods to remove
DOAC from the plasma sample, without affecting the char-
acteristics of the clotting abnormalities.8,41 Another possi-
bility to reduce the impact of betrixaban is to increase the
dilution of the sample (i.e., at least 1:40). Measurement of
protein S does not seem to be influenced until 10 ng/mL of
betrixaban but show an over-estimation of approximately
10% at 30 ng/mL.
In clinical routine practice, it is preferable to use assays
that do not involve FX since they are not influenced by
betrixaban like immunological assays but these do not assess
the activity and have higher turn-around time.
Conclusions and Perspectives
Our results demonstrate an important lack of sensitivity for
routine tests as reported for other DOACs. As it has been
observed with other DOACs, chromogenic anti-Xa assays
seem to be interesting candidates to assess the presence of
low levels of betrixaban, below 120 ng/mL, but adapted
methodologies should be evaluated to improve sensitivity
of these reagents for on-therapy range. However, this study
shows that adapted-chromogenic anti-Xa assays are the
most appropriate assays tomeasure the anti-coagulant effect
of betrixaban. Broadly used coagulation assays such as PT or
aPTT are not appropriate to efficiently estimate plasma drug
concentration due to several limitations and a lack of sensi-
tivity. The dRVV-T could be informative in certain circum-
stances due to its good sensitivity and its low LOQ. CAT gives
further information on the coagulation process but its use in
clinical settings is limited. Finally, betrixaban significantly
affects several haemostasis diagnostic tests, such as LA or
other thrombophilia testing, and this needs to be taken into
consideration when requesting and interpreting such tests.
Table 2 Summary of recommended assays for the measurement of betrixaban in plasma
Useful for measurement Reliable but
requires
laboratory
experience
Not recommended
Chromogenic
anti-Xa assays
dRVVT TGA PT aPTT TT RT
Sensitivity (ng/mL) 1–72 5–6a Peak: 37–58
mVRI: 17–27
5–36 16–57 Insensitive
Dynamic range of
quantitation (ng/mL)b
4–231 3–231 Peak: 122–231
mVRI: 60–231
11–231 21–231 NA
Repeatability (%) 0.6–3.1 0.8–0.9 3.1–8.9 0.5–1.1 0.4–1.2 NA
Dependence of
reagent
Yes Yes Yes Yes Yes No
Linearity of the
response
Yes but further
investigations
required
No No Yes Yes NA
Abbreviations: aPTT, activated partial thromboplastin time; dRVVT, dilute Russell viper venom time; FDA, Food and Drug Administration; mVRI,
mean velocity rate index; NA, not applicable; PT: pro-thrombin time; RT, reptilase time; TGA, thrombin generation assay; TT, thrombin time.
Note: The on-therapy range of concentration for betrixaban is from  9 ng/mL at Ctrough to  122 ng/mL at Cmax for the 40 and 120 mg once daily
doses, respectively (according to the clinical pharmacology and biopharmaceutics reviews of the Center for Drug Evaluation and Research of the
FDA16).
a5 ng/mL and 6 ng/mL for STA-Staclot-DRVV Screen and Confirm, respectively.
bDynamic range of quantification is defined as range covering from the lowest observed limit of quantification to the maximal concentration tested.
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